Stock comparison
Pro Medicus Limited
PME.AX$19.19BHealthcare Market cap, Sector
Rigel Pharmaceuticals
RIGL$761.95MHealthcare Market cap, Sector
Overall winner
Pro Medicus Limited
PME.AX 70 RIGL
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
PME.AX7wins
0winsRIGL
78B
D47
90A
F34
98A
D54
100A
D54
84B
D48
91A
C62
96A
C61
Side-by-side metrics
| Metric | PME.AX | RIGL |
|---|---|---|
| Market cap | Winner: $19.19B | $761.95M |
| P/E (TTM) | 147.6x | 1.4x Winner |
| EV/EBIT | 106.8x | 4.3x Winner |
| ROIC (TTM) | Winner: 42.56% | 27.96% |
| Gross margin | Winner: 99.85% | 93.39% |
| Net margin | 54.12% | 121.51% Winner |
| Revenue CAGR 5y | Winner: 31.61% | 18.5% |
| EPS CAGR 5y | 37.34% | - |
| Debt / Equity | Winner: 0.0x | 0.1x |
| Dividend yield | - | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
PME.AX leads on
- Market cap$19.19Bvs $761.95M+96%
- Debt / Equity0.0xvs 0.1x+92%
- Revenue CAGR 5y31.61%vs 18.5%+41%
- ROIC (TTM)42.56%vs 27.96%+34%
RIGL leads on
- P/E (TTM)1.4xvs 147.6x+99%
- EV/EBIT4.3xvs 106.8x+96%
- Net margin121.51%vs 54.12%+55%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.